Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

Relapsed myeloid disease after allogeneic stem cell transplantation (HSCT) remains largely incurable. We previously demonstrated the potent activity of immune checkpoint blockade in this clinical setting with ipilimumab or nivolumab. To define the molecular and cellular pathways by which CTLA-4 bloc...

Descripción completa

Detalles Bibliográficos
Autores principales: Penter, Livius, Zhang, Yi, Savell, Alexandra, Huang, Teddy, Cieri, Nicoletta, Thrash, Emily M., Kim-Schulze, Seunghee, Jhaveri, Aashna, Fu, Jingxin, Ranasinghe, Srinika, Li, Shuqiang, Zhang, Wandi, Hathaway, Emma S., Nazzaro, Matthew, Kim, Haesook T., Chen, Helen, Thurin, Magdalena, Rodig, Scott J., Severgnini, Mariano, Cibulskis, Carrie, Gabriel, Stacey, Livak, Kenneth J., Cutler, Corey, Antin, Joseph H., Nikiforow, Sarah, Koreth, John, Ho, Vincent T., Armand, Philippe, Ritz, Jerome, Streicher, Howard, Neuberg, Donna, Hodi, F. Stephen, Gnjatic, Sacha, Soiffer, Robert J., Liu, X. Shirley, Davids, Matthew S., Bachireddy, Pavan, Wu, Catherine J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology 2021
Materias:
CLINICAL TRIALS AND OBSERVATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8351891/
https://www.ncbi.nlm.nih.gov/pubmed/33720354
http://dx.doi.org/10.1182/blood.2021010867

Ejemplares similares

Ejemplares similares